Market Intelligence Ecosystem
Sun Pharmaceutical Industries Limited (NSE: SUNPHARMA) Q3 FY23 Earnings Concall dated Jan. 31, 2023 Corporate Participants: Abhishek Sharma -- Head of Investor Relations and
Key highlights from Torrent Pharmaceuticals Ltd (TORNTPHARM) Q3 FY23 Earnings Concall Management Update: [00:05:39] TORNTPHARM said the company expects to file about
Torrent Pharmaceuticals Ltd (NSE: TORNTPHARM) Q3 FY23 Earnings Concall dated Jan. 25, 2023 Corporate Participants: Sudhir Menon -- Executive Director, (Finance) and Chief Financial
Indoco Remedies Limited (NSE: INDOCO) Q3 FY23 Earnings Concall dated Jan. 24, 2023 Corporate Participants: Aditi Panandikar -- Managing Director Sundeep V. Bambolkar -- Joint Managing
Granules India Ltd (NSE: GRANULES) Q3 FY23 Earnings Concall dated Jan. 24, 2023 Corporate Participants: Irfan Raeen -- Investor Relation Advisor Krishna Prasad Chigurupati -- Chairman
Syngene International Ltd (NSE: SYNGENE) Q3 FY23 Earnings Concall dated Jan. 24, 2023 Corporate Participants: Avantika Mishra -- Associate - EY Jonathan Hunt -- Managing Director
Syngene International Ltd (NSE: SYNGENE) Q3 FY23 Earnings Concall dated January 24, 2023 Corporate Participants: Avantika Mishra -- Associate - EY Jonathan Hunt -- Managing Director
Gland Pharma Limited (NSE:GLAND) Q3 FY23 Earnings Concall dated Jan. 23, 2023. Corporate Participants: Sumanta Bajpayee -- Vice President, Finance and Investor Relations Srinivas
“Our hospital business is on a very strong growth trajectory and will continue to grow. We will improve not only in revenues
Shalby Ltd.‘s revenues in Q2FY23 rose 11% to ₹ 2,018 millions. Consolidated Profit After Tax came at ₹ 184 millions showcasing a
“With all key strategies in place, our team is extremely committed to flawless execution of these strategies. Shalby is very well poised
IOL Chemicals and Pharmaceuticals Limited (NSE:IOLCP) Q2 FY23 Earnings Concall dated Nov. 15, 2022 Corporate Participants: Sanjay Chaturvedi -- Executive Director and Chief Executive
Biocon Limited (NSE: BIOCON) Q2 FY23 Earnings Concall dated Nov. 14, 2022 Corporate Participants: Saurabh Paliwal -- Head, Investor Relations Kiran Mazumdar
Glenmark Pharmaceuticals Limited (NSE: GLENMARK) Q2 FY23 Earnings Concall dated Nov. 13, 2022 Corporate Participants: Utkarsh Gandhi -- General Manager - Investor Relations Brendan
Alembic Pharmaceuticals Limited (NSE:APLLTD) Q2 FY23 Earnings Concall dated Nov. 11, 2022 Corporate Participants: Raj Kumar Baheti -- Director - Finance and Chief Financial
Healthcare Global Enterprises Ltd (NSE:HCG) Q2 FY22 Earnings Concall dated Nov. 11, 2022 Corporate Participants: B.S. Ajai Kumar -- Executive Chairman Raj
Indoco Remedies Limited (NSE:INDOCO) Q2 FY23 Earnings Concall dated Nov. 11, 2022 Corporate Participants: Aditi Panandikar -- Managing Director Sundeep Bambolkar --
Dishman Carbogen Amcis Ltd (NSE: DCAL) Q2 FY22 Earnings Concall dated Nov. 11, 2022 Corporate Participants: Arpit Vyas -- Global Managing Director Pascal Villemagne -- Vice
Aster DM Healthcare Limited (NSE:ASTERDM) Q2 FY23 Earnings Concall dated Nov. 11, 2022 Corporate Participants: Azad Moopen -- Chairman & Managing Director
https://youtu.be/-5pgj3qU44c Key highlights from Sequent Scientific Limited (SEQUENT) Q2 FY23 Earnings Concall Q&A Highlights: [00:17:40] Rishab Jain asked about Tineta Pharma acquisition,
Zydus Wellness Ltd (NSE:ZYDUSWELL)Q2 FY23 Earnings Concall dated Nov. 10, 2022 Corporate Participants: Tarun Arora -- Chief Executive Officer, Whole Time Director